Enveric Biosciences (ENVB) Cash from Investing Activities (2014 - 2023)
Enveric Biosciences (ENVB) posted Cash from Investing Activities of -$38.0 for Q4 2023, down 290.0% sequentially from $20.0 in Q3 2023, and up 99.39% YoY from -$19.06 in Q4 2022.
Enveric Biosciences (ENVB) Cash from Investing Activities (2014 - 2023) Analysis & Trends
Enveric Biosciences has reported Cash from Investing Activities for 10 years, with the latest figure at -$38.0 in Q4 2023.
- Quarterly Cash from Investing Activities rose 99.39% year-over-year to -$38.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $11667.0 (up 102.0% YoY) and the FY2023 annual result came in at $11667.0, up 102.0% from the prior year.
- Cash from Investing Activities declined to -$38.0 in Q4 2023 per ENVB's latest filing, from $20.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $3.1 million in Q3 2021 and troughed at -$675000.0 in Q1 2021.
- A 5-year average of $71646.5 and a median of -$12383.5 in 2022 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 49643.17% in 2021, down 9619.22% in 2021.
- Over 5 years, Cash from Investing Activities stood at -$56633.0 in 2019, then jumped by 103.52% to $1993.0 in 2020, then tumbled by 9619.22% to -$189718.0 in 2021, then surged by 96.74% to -$6193.0 in 2022, then soared by 99.39% to -$38.0 in 2023.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$38.0, $20.0, and $16854.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -38.00 |
| Dec 31, 2023 | -38.00 |
| Sep 30, 2023 | 20.00 |
| Sep 30, 2023 | 20.00 |
| Jun 30, 2023 | 16,854.00 |
| Jun 30, 2023 | 16,854.00 |
| Mar 31, 2023 | -5,169.00 |
| Mar 31, 2023 | -5,169.00 |
| Dec 31, 2022 | -6,193.00 |
| Dec 31, 2022 | -6,193.00 |
| Sep 30, 2022 | -18,574.00 |
| Sep 30, 2022 | -18,574.00 |
| Jun 30, 2022 | -53,891.00 |
| Jun 30, 2022 | -53,891.00 |
| Mar 31, 2022 | -505,507.00 |
| Mar 31, 2022 | -505,507.00 |
| Dec 31, 2021 | -189,718.00 |
| Dec 31, 2021 | -189,718.00 |
| Sep 30, 2021 | 3.06 Mn |
| Sep 30, 2021 | 3.06 Mn |